Continuity Biosciences

Executive Summary

Continuity Biosciences is a preclinical-stage biotechnology company developing adaptive, precision delivery platforms that address critical limitations in therapeutic administration. Founded in 2021 and headquartered in Cambridge, Massachusetts, the company merges medtech and biotech expertise to create implantable and localized systems that guide drugs—ranging from small molecules to cell-based therapies—to specific targets within the body. Its mission is to amplify therapeutic efficacy by solving delivery challenges in diabetes, oncology, HIV, and other chronic diseases. The technology aims to reduce systemic toxicity, improve patient compliance, and enable new treatment modalities that were previously limited by off-target effects or rapid clearance. While the company remains in early development with limited public information, its platform approach has broad applicability across multiple high-value therapeutic areas. Continuity Biosciences has not disclosed specific products, funding rounds, or clinical timelines, but its focus on precision delivery aligns with industry trends toward localized and sustained-release therapies. The company's success will depend on demonstrating preclinical proof-of-concept, securing partnerships, and advancing a lead program toward the clinic. Given the early stage and lack of disclosed data, conviction in the company's near-term prospects is moderate.

Upcoming Catalysts (preview)

• Q4 2026Lead Program Preclinical Proof-of-Concept Data60% success
• TBDSeries A/B Financing70% success
• TBDStrategic Partnership with Pharmaceutical Company50% success